CAOP - Competency Assessment of Overseas Pharmacist Monitoring Medication Outcomes Questions and Answers — Questions and Answers
Question 1: A 68-year-old male patient on long-term warfarin therapy for atrial fibrillation presents to your pharmacy with a new prescription for amiodarone. His INR has been stable for the past six months, consistently between 2.0 and 3.0. What is the most critical monitoring parameter to assess following the initiation of amiodarone?
- Liver function tests (LFTs) within one month.
- Serum potassium levels within two weeks.
- International Normalised Ratio (INR) within one week. (Correct answer)
- Thyroid function tests (TFTs) at three months.
Correct answer: International Normalised Ratio (INR) within one week.
Amiodarone is a potent inhibitor of the cytochrome P450 enzymes that metabolise warfarin, leading to a significant drug-drug interaction. This interaction can markedly increase the patient's INR, elevating the risk of bleeding. Therefore, the INR must be monitored closely, typically within a week of starting amiodarone, and the warfarin dose will likely require a significant reduction.
Question 2: Which of the following is a key criterion for a drug to be considered suitable for Therapeutic Drug Monitoring (TDM)?
- The drug has a wide therapeutic range.
- A clear relationship exists between plasma concentration and clinical effect. (Correct answer)
- The drug exhibits minimal pharmacokinetic variability between individuals.
- An inexpensive and readily available antidote exists.
Correct answer: A clear relationship exists between plasma concentration and clinical effect.
Therapeutic Drug Monitoring (TDM) is most valuable when there is a well-established relationship between the drug's concentration in the plasma and its therapeutic or toxic effects. Drugs with a narrow therapeutic range and significant pharmacokinetic variability are also prime candidates for TDM, as it helps to individualise dosing to ensure efficacy while avoiding toxicity.
Question 3: A pharmacist is conducting a Home Medicines Review (HMR) for an elderly patient who reports increased drowsiness and confusion since starting a new medication for insomnia a month ago. Which of the following is the pharmacist's most important immediate action regarding medication outcomes?
- Advise the patient to immediately cease the insomnia medication.
- Document the suspected adverse drug reaction (ADR) and report it to the Therapeutic Goods Administration (TGA).
- Recommend a lower dose of the medication to the patient.
- Contact the patient's GP to discuss the suspected ADR and recommend a management plan. (Correct answer)
Correct answer: Contact the patient's GP to discuss the suspected ADR and recommend a management plan.
While reporting the ADR to the TGA is important for pharmacovigilance, the pharmacist's primary responsibility is the immediate safety and care of the patient. This involves collaborative practice with the prescriber (the GP) to assess the situation and make a therapeutic decision. The pharmacist should communicate their findings and concerns to the GP to facilitate a timely review and potential adjustment of the patient's therapy. Advising the patient to cease medication unilaterally is outside the pharmacist's scope of practice.
Question 4: When monitoring a patient on gentamicin therapy, a pharmacist notes a higher-than-expected trough level. This finding primarily indicates an increased risk of which of the following adverse effects?
- Hepatotoxicity
- Cardiotoxicity
- Ototoxicity (Correct answer)
- Photosensitivity
Correct answer: Ototoxicity
Gentamicin is an aminoglycoside antibiotic known for its potential to cause nephrotoxicity and ototoxicity. Trough concentrations are monitored to ensure the drug is being adequately cleared from the body between doses. Elevated trough levels indicate accumulation and are strongly associated with an increased risk of toxicity, particularly to the ears (ototoxicity) and kidneys (nephrotoxicity).
Question 5: According to the National Competency Standards Framework for Pharmacists in Australia, monitoring medication outcomes is a core component of which domain?
- Professional and Ethical Practice
- Communication and Collaboration
- Review and Manage Medication Management Plans (Correct answer)
- Leadership and Management
Correct answer: Review and Manage Medication Management Plans
The National Competency Standards Framework for Pharmacists in Australia (2016) outlines the required skills and knowledge for pharmacists. The domain that encompasses formulating, implementing, and monitoring the outcomes of medication management plans is 'Domain 3: Review and Manage Medication Management Plans'. This includes assessing the patient's response to therapy and recommending adjustments as needed.
Question 6: A patient with newly diagnosed epilepsy is commenced on phenytoin. To ensure the patient reaches a therapeutic and safe steady-state concentration, what information is most crucial for the pharmacist to provide?
- Information about common side effects like gingival hyperplasia.
- The importance of consistent dosing times and adherence. (Correct answer)
- Advice to take the medication with a large glass of grapefruit juice.
- A reminder to get their blood pressure checked weekly.
Correct answer: The importance of consistent dosing times and adherence.
Phenytoin exhibits non-linear (or saturable) pharmacokinetics, meaning that small changes in dose can lead to disproportionately large changes in plasma concentration, especially as the metabolising enzymes approach saturation. Therefore, strict adherence to the prescribed dose and consistent timing of administration are critical to avoid sub-therapeutic levels or toxicity. While counselling on side effects is important, ensuring consistent intake is paramount for monitoring and achieving a predictable outcome.
CAOP - Competency Assessment of Overseas Pharmacist Monitoring Medication Outcomes Questions and Answers
A 68-year-old male patient on long-term warfarin therapy for atrial fibrillation presents to your pharmacy with a new prescription for amiodarone.
His INR has been stable for the past six months, consistently between 2.0 and 3.0.
What is the most critical monitoring parameter to assess following the initiation of amiodarone?